Duality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026

Reuters

11 hours ago

Duality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026

Duality Biotherapeutics Inc. announced updated efficacy and safety results from its Phase 1/2 DB-1311-O-1001 study (NCT05914116) evaluating DB-1311/BNT324, an investigational B7-H3 antibody-drug conjugate, in heavily pretreated metastatic castration-resistant prostate cancer. The company said the data will be presented at the ASCO Genitourinary Cancers Symposium 2026 (February 26–28, 2026) and that the study abstract was published on the symposium website on February 23, 2026. As of the September 5, 2025 data cutoff, 104 patients had been treated; among 58 response-evaluable patients, confirmed objective response rate was 34.5% and disease control rate was 87.9%, with median radiographic progression-free survival of 11.3 months in 82 evaluable patients; outcomes were reported as similar in patients with and without prior lutetium-177 PSMA-617 treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260224-12028077), on February 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613275840"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613275840\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613275840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 06:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613275840","market":"fut","top_or_hot":-1,"title":"Duality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Duality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Duality Biotherapeutics Inc. announced updated efficacy and safety results from its Phase 1/2 DB-1311-O-1001 study (NCT05914116) evaluating DB-1311/BNT324, an investigational B7-H3 antibody-drug conjugate, in heavily pretreated metastatic castration-resistant prostate cancer. The company said the data will be presented at the ASCO Genitourinary Cancers Symposium 2026 (February 26–28, 2026) and that the study abstract was published on the symposium website on February 23, 2026. As of the September 5, 2025 data cutoff, 104 patients had been treated; among 58 response-evaluable patients, confirmed objective response rate was 34.5% and disease control rate was 87.9%, with median radiographic progression-free survival of 11.3 months in 82 evaluable patients; outcomes were reported as similar in patients with and without prior lutetium-177 PSMA-617 treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260224-12028077), on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Duality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDuality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 06:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Duality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Duality Biotherapeutics Inc. announced updated efficacy and safety results from its Phase 1/2 DB-1311-O-1001 study (NCT05914116) evaluating DB-1311/BNT324, an investigational B7-H3 antibody-drug conjugate, in heavily pretreated metastatic castration-resistant prostate cancer. The company said the data will be presented at the ASCO Genitourinary Cancers Symposium 2026 (February 26–28, 2026) and that the study abstract was published on the symposium website on February 23, 2026. As of the September 5, 2025 data cutoff, 104 patients had been treated; among 58 response-evaluable patients, confirmed objective response rate was 34.5% and disease control rate was 87.9%, with median radiographic progression-free survival of 11.3 months in 82 evaluable patients; outcomes were reported as similar in patients with and without prior lutetium-177 PSMA-617 treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260224-12028077), on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252152.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL32V5N0:1","article_id":"2613275840","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613275840","pubTimestamp":1771884238,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Duality Biotherapeutics Inc. announced updated efficacy and safety results from its Phase 1/2 DB-1311-O-1001 study  evaluating DB-1311/BNT324, an investigational B7-H3 antibody-drug conjugate, in heavily pretreated metastatic castration-resistant prostate cancer. The company said the data will be presented at the ASCO Genitourinary Cancers Symposium 2026  and that the study abstract was published on the symposium website on February 23, 2026. As of the September 5, 2025 data cutoff, 104 patients had been treated; among 58 response-evaluable patients, confirmed objective response rate was 34.5% and disease control rate was 87.9%, with median radiographic progression-free survival of 11.3 months in 82 evaluable patients; outcomes were reported as similar in patients with and without prior lutetium-177 PSMA-617 treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","BK1161":"生物科技","09606":"映恩生物-B","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元"},"translate_title":"Duality Biotherapeutics将在ASCO GU 2026上展示更新的DB-1311/BNT324 1/2期mCRPC数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":0.9},"content_text":"Duality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026\n    \n\n        Duality Biotherapeutics Inc. announced updated efficacy and safety results from its Phase 1/2 DB-1311-O-1001 study (NCT05914116) evaluating DB-1311/BNT324, an investigational B7-H3 antibody-drug conjugate, in heavily pretreated metastatic castration-resistant prostate cancer. The company said the data will be presented at the ASCO Genitourinary Cancers Symposium 2026 (February 26–28, 2026) and that the study abstract was published on the symposium website on February 23, 2026. As of the September 5, 2025 data cutoff, 104 patients had been treated; among 58 response-evaluable patients, confirmed objective response rate was 34.5% and disease control rate was 87.9%, with median radiographic progression-free survival of 11.3 months in 82 evaluable patients; outcomes were reported as similar in patients with and without prior lutetium-177 PSMA-617 treatment.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260224-12028077), on February 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}